FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells
Article in Biomedicine & Pharmacotherapy (September 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Biomedicine & Pharmacotherapy (September 2024)
Preprint in bioRxiv (November 2023)